Ring Therapeutics to Present Data on Anellogy Platform at the ESGCT 28th Annual Congress

CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) — Ring Therapeutics (“Ring”), a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today announced preclinical data highlighting its Anellogy™ platform. The data validates the potential to utilize anelloviruses as a new class of gene therapy vectors with potential to address notable industry challenges such as tropism, safety, immunogenicity and redosing. Results will be presented at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) taking place virtually from October 19-22, 2021.

Click here to view original post